Sitawar-GM2

Sitawar-GM2 is a balanced triple-combination therapy formulated with sitagliptin 50 mg, glimepiride 2 mg, and metformin HCl 1000 mg for the treatment of type 2 diabetes mellitus. The combination works through complementary mechanisms to help improve blood sugar control and support long-term glycemic management. Sitagliptin helps enhance incretin hormone activity to support insulin release after meals, glimepiride stimulates insulin secretion from the pancreas, and metformin helps reduce glucose production in the liver while improving insulin sensitivity. Together, the combination supports better fasting and post-meal blood sugar control as part of an overall diabetes care plan that includes diet, exercise, and lifestyle modification.

How Does Sitawar-GM2 (Sitagliptin 50 mg + Glimepiride 2 mg + Metformin HCl 1000 mg) Work?

• Sitagliptin (50 mg): DPP-4 Inhibitor. Inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), increasing levels of active incretin hormones (GLP-1 and GIP). This mechanism enhances glucose-dependent insulin secretion and decreases glucagon secretion.
• Glimepiride (2 mg): Sulfonylurea (insulin secretagogue) Stimulates functioning pancreatic beta cells to release more insulin.
• Metformin (1000mg): Biguanide. Reduces hepatic glucose output, improves peripheral insulin sensitivity (increasing glucose uptake/utilization), and reduces intestinal absorption of glucose.

Regular therapy along with healthy lifestyle practices may help support long-term diabetes management and metabolic balance.

Clinical Benefits

• Helps support effective management of fasting and post-meal blood sugar levels.
• Supports overall glycemic control in adults with type 2 diabetes mellitus.
• Helps improve insulin secretion and insulin utilization in the body.
• Metformin supports reduction in excess glucose production from the liver.
• May help support long-term HbA1c management when combined with diet and exercise.
• Fixed-dose triple therapy offers convenience and may help improve treatment adherence.

Dosage & Administration

Sitawar-GM2 should be taken strictly under medical supervision and as directed by the physician. The dosage may vary depending on the patient’s blood glucose levels, clinical condition, kidney function, and response to treatment. Patients are advised to continue regular blood sugar monitoring, maintain a balanced diet, and follow lifestyle modifications during therapy.

Disclaimer

To be used under medical supervision only. The information provided is for educational purposes and should not replace professional medical advice, diagnosis, or treatment.